Peripheral vascular disease is on the rise and peripheral PCI is at present the first choice of treatment for most patients. The use of IVUS in femoropopliteal territory has shown great benefits, especially in left main and complex PCI, reducing mortality and restenosis but, though promising, in lower limb ischemia we have little information as<a href="https://solaci.org/en/2023/05/10/is-ivus-useful-in-lower-limb-pci/" title="Read more" >...</a>
PICCOLETO-II: Drug-Coated Balloons in Small Vessels
Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>
Comparative Study of Two Drug Coated Balloons: Angiographic and Clinical Outcomes
The incidence of in-stent restenosis (ISR) requiring repeat revascularization ranges between 5% and 10% of PCI patients receiving new generation drug eluting stents (DES). This is why the current European guidelines on myocardial revascularization recommend treating ISR with drug coated balloons (DCB) with class I recommendation, level of evidence A. DCB are mostly coated with<a href="https://solaci.org/en/2023/04/21/comparative-study-of-two-drug-coated-balloons-angiographic-and-clinical-outcomes/" title="Read more" >...</a>
CTO: Length’s Impact on Success
The rise of chronic total occlusions (CTO) percutaneous coronary interventions (PCI) goes hand in hand with technological development, through still posing a great challenge, one not exactly exempt from complications. An important criterion to successful CTO PCI is length: ≥20 mm lesions lower the odds, according to J-CTO Score. However, increasing operator experience and the<a href="https://solaci.org/en/2023/04/13/cto-lengths-impact-on-success/" title="Read more" >...</a>
ISAR Score: Can We Predict the Need for Repeat PCI in DES Restenosis?
Score to predict the risk of repeat PCI in DES restenosis. With the use of drug eluting stents (DES) instent restenosis (ISR) has seen a significant reduction vs. bare metal stents (BMS) restenosis. The main cause of DES failure is ISR. This entity is difficult to manage because of its high recurrence and reintervention risk.<a href="https://solaci.org/en/2023/04/12/isar-score-can-we-predict-the-need-for-repeat-pci-in-des-restenosis/" title="Read more" >...</a>
AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography
Several studies have used physiological assessment after a percutaneous coronary intervention (PCI) to improve clinical outcomes. However, results are not entirely conclusive. The limitations of using these physiological assessment methods are the need for extra measurements with increased procedure time, more radiation, and more contrast, which in turn leads to higher costs. To counteract these<a href="https://solaci.org/en/2023/04/05/aqca-study-pre-pci-virtual-qfr-for-planning-pci-vs-conventional-angiography/" title="Read more" >...</a>
SAFE-AAA: Are the New Endologix Devices for Abdominal Aortic Aneurysm Safe? 3-Year Followup
New unibody endologix endografts for the endovascular repair of abdominal aortic aneurysm 3-4-year safety followup At present, we have seen endovascular intervention of abdominal aortic aneurysm (EVAR) increase over surgical repair. However, the procedure is not free from complications, endoleak being the most frequent. Indeed, according to different series, it has a 20-25% incidence in AAA. Most<a href="https://solaci.org/en/2023/03/30/safe-aaa-are-the-new-endologix-devices-for-abdominal-aortic-aneurysm-safe-3-year-followup/" title="Read more" >...</a>
The most read scientific articles in interventional cardiology in February on our website
Below, we share February’s most read scientific abstracts in interventional cardiology at solaci.org. Can Drug Coated Balloon Be a Valid Option for Small Vessels? One of the challenges of percutaneous coronary interventions (PCI) are <2.5 mm vessels, since complications and restenosis complications rate are higher than with >3.0 mm vessels. Is Using Drug-Eluting Balloons and<a href="https://solaci.org/en/2023/03/22/the-most-read-scientific-articles-in-interventional-cardiology-in-february-on-our-website/" title="Read more" >...</a>
ACC 2023 | RENOVATE-COMPLEX-PCI: Intravascular Imaging-Guided vs. Angiography-Guided Complex PCI
Patients with complex coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) have worse clinical outcomes tan patients with non-complex CAD. Several studies have shown that the use of intravascular imaging (IVUS, OCT) have reduced major adverse events vs. angiography guided PCI. However, these studies present limitations both of size, studied population, short term followup<a href="https://solaci.org/en/2023/03/08/acc-2023-renovate-complex-pci-intravascular-imaging-guided-vs-angiography-guided-complex-pci/" title="Read more" >...</a>
Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons
Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or<a href="https://solaci.org/en/2023/02/22/arterial-patency-in-femoropopliteal-disease-with-drug-eluting-balloons/" title="Read more" >...</a>